01 1Actilyse/Metalyse
02 1Activacin
03 6Activase/TNKase
04 1Activase/Tnkase
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 1,372
2018 Revenue in Millions : 1,323
Growth (%) : 4
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 1,472
2019 Revenue in Millions : 1,484
Growth (%) : -1
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 1,412
2020 Revenue in Millions : 1,400
Growth (%) : -1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 1,287
2021 Revenue in Millions : 1,412
Growth (%) : -9
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 1,361
2022 Revenue in Millions : 1,287
Growth (%) : 0
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 713
2023 Revenue in Millions : 617
Growth (%) : 16
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 1,324
2023 Revenue in Millions : 1,361
Growth (%) : -3
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 10
2017 Revenue in Millions : 0
Growth (%) : New Launch
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 1,297
2017 Revenue in Millions : 1,231
Growth (%) : 5%
